AIM ImmunoTech Inc
LSE:0A4Y
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
A
|
AIM ImmunoTech Inc
AMEX:AIM
|
3.5m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.1B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
190B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.4B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
AIM ImmunoTech Inc
Glance View
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 21 full-time employees. The firm is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The firm's products are Alferon N Injection and Ampligen. Alferon N Injection is a natural-source, glycosylated, multi-species alpha interferon product. Alferon is used for the treatment of refractory (resistant to other treatment) or recurring external genital warts in patients 18 years of age or older. Ampligen (rintatolimod), which is a drug of macromolecular RNA (ribonucleic acid) molecules, it is a sterile solution indicated for the treatment of severely debilitated patients with Chronic Fatigue Syndrome (CFS) who have been diagnosed for longer than one year. Ampligen is used in combination with checkpoint blockade therapies. Ampligen is also being used as a monotherapy to treat pancreatic cancer patients.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for AIM ImmunoTech Inc is -13 360.3%, which is below its 3-year median of -12 561.4%.
Over the last 3 years, AIM ImmunoTech Inc’s Net Margin has decreased from -12 563.7% to -13 360.3%. During this period, it reached a low of -16 123.3% on Mar 31, 2024 and a high of -10 188.2% on Dec 31, 2024.
